Inhibitory Effects of Lactoferrin on Biofilm Formation in Clinical Isolates of Pseudomonas Aeruginosa
Dieses Format: Bentigt keine Khlung oder Stabilisatoren , was die Integritt des Wirkstoffs bei Raumtemperatur bewahrt
For example, ester, phosphate, carbamate
Primary risk factors: high doses, rapid escalation, concurrent ICI therapy, pre-existing liver disease, and no routine monitoring
Martinez 6,7 , Maria Galn 8,9* , Affiliation: 1 Group of Endocrinology, Diabetes and Nutrition, Institut de Recerca Sant Pau, 08041 Barcelona, Spain 2 CIBER of Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain Email: [email protected] ORCID: Josep Julve 1,2* Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), is a complex chronic metabolic dysfunction of the liver influenced by both genetic and non-genetic factors [1]